Business
Cellectis Abandons CAR-T to Bet Its Future on Editing Genes Inside the Body
A pioneer of donor-derived cell therapy is walking away from cancer CAR-T — battered by competition — and pivoting to in vivo gene editing for heart disease. Investors sent the stock down 43%.